TC
ONCT

TFS Capital’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

TFS Capital’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-349
Closed -$805K – 1627
2013
Q4 		$805K Buy
349
+271
+347% +$620K 0.04% 643
2013
Q3 		$222K Buy
+78
New +$388K 0.01% 1219

Other funds holding ONCT

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TFS Capital's ONCT Position: Q1 2014 in Review

TFS Capital sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2014, closing a stake of 349 shares — an estimated $805K sold.

TFS Capital first reported a position in ONCT in Q3 2013 and held it in 2 quarters. The position peaked at $805K in Q4 2013. 55 funds tracked by Wall St. Rank hold ONCT as of Q1 2014.

  • TFS Capital reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2014 after selling out during the quarter.
  • TFS Capital sold 349 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2014, an estimated $805K.
  • TFS Capital first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2013 and held it in 2 quarters.
  • TFS Capital's Oncternal Therapeutics, Inc. Common Stock position peaked at $805K in Q4 2013.
  • 55 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2014.

Based on TFS Capital's 13F filing for Q1 2014, filed 5 May 2014.